Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
Healthcare
$15.53 -1.20%
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
52W Low $14.23High $28.00
Volume 0.34M
Average 0.45M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$59.20M
FY 2025 · Annual
Investing Cash Flow
-$73.45M
FY 2025 · Annual
Financing Cash Flow
$142.01M
FY 2025 · Annual
+71.6% YoYCash Flow Statement
USD
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (45.05M) | (60.9M) |
| Depreciation & Amortization | 313K | 804K |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 1.54M | 276K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 1.72M | 180K |
| Other Working Capital | (181K) | 96K |
| Other Non-Cash Items | 8.16M | 619K |
| Operating Cash Flow | (35.04M) | (59.2M) |
| Capital Expenditures | (1.77M) | (2.31M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (46.03M) | (221.89M) |
| Sales of Investments | 8M | 150.75M |
| Other Investing Activities | 0 | 0 |
| Investing Cash Flow | (39.8M) | (73.46M) |
| Debt Repayment | (171K) | 0 |
| Common Stock Issued | 82.92M | 142.01M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 82.75M | 142.01M |
| Effect of Forex Changes | 22.73M | 203K |
| Net Change in Cash | 30.63M | 9.56M |
| Free Cash Flow | (36.81M) | (61.51M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$60.9M
+ D&A$804.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$276.0K
+ Other Non-Cash$619.0K
= Operating Cash Flow-$59.2M
- Capex-$2.3M
= Free Cash Flow-$61.5M
Analysis
FY2025 free cash flow is -$61.5M. FCF conversion is 101.0% of net income. Operating cash flow was -$59.2M, with capex of -$2.3M. The largest bridge item is Capex at -$2.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 3/A | 3/A filing | Oct 8, 2026 |
Does ATTO generate free cash flow?
Attovia Therapeutics, Inc. (ATTO) generated -$61.51M of free cash flow in fiscal 2025.
How much operating cash flow does ATTO produce?
Operating cash flow was -$59.20M, before capital expenditures of $2.31M.
Continue the stock analysis
Jump to another research area for this company.